237 related articles for article (PubMed ID: 14558604)
1. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.
Thiessen B; Maguire JA; McNeil K; Huntsman D; Martin MA; Horsman D
J Neurooncol; 2003 Sep; 64(3):271-8. PubMed ID: 14558604
[TBL] [Abstract][Full Text] [Related]
2. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
Ramirez C; Bowman C; Maurage CA; Dubois F; Blond S; Porchet N; Escande F
Neuro Oncol; 2010 May; 12(5):490-9. PubMed ID: 20156805
[TBL] [Abstract][Full Text] [Related]
3. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.
Felsberg J; Erkwoh A; Sabel MC; Kirsch L; Fimmers R; Blaschke B; Schlegel U; Schramm J; Wiestler OD; Reifenberger G
Brain Pathol; 2004 Apr; 14(2):121-30. PubMed ID: 15193024
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
[TBL] [Abstract][Full Text] [Related]
5. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
[TBL] [Abstract][Full Text] [Related]
7. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
[TBL] [Abstract][Full Text] [Related]
8. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
9. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
[TBL] [Abstract][Full Text] [Related]
10. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
[TBL] [Abstract][Full Text] [Related]
11. Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.
Michaud K; de Tayrac M; D'Astous M; Duval C; Paquet C; Samassekou O; Gould PV; Saikali S
PLoS One; 2016; 11(12):e0168728. PubMed ID: 28030632
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status?
Campbell BA; Horsman DE; Maguire J; Young S; Curman D; Ma R; Thiessen B
J Neurooncol; 2008 Aug; 89(1):37-45. PubMed ID: 18458822
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.
Li J; Miao N; Liu M; Cui W; Liu X; Li X; Shi X; Qing S; Ma Y; Zhang W; Biekemituofu H
Int J Clin Exp Pathol; 2014; 7(12):8609-15. PubMed ID: 25674225
[TBL] [Abstract][Full Text] [Related]
14. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
[TBL] [Abstract][Full Text] [Related]
15. [Significance and prospects of study on molecular alterations in oligodendrogliomas].
Gresner SM; Liberski PP
Neurol Neurochir Pol; 2007; 41(4):333-9. PubMed ID: 17874342
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic alterations in glioblastomas with oligodendroglial component.
Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
[TBL] [Abstract][Full Text] [Related]
17. The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.
Horbinski C; Nikiforova MN; Hobbs J; Bortoluzzi S; Cieply K; Dacic S; Hamilton RL
J Neuropathol Exp Neurol; 2012 Jan; 71(1):73-82. PubMed ID: 22157622
[TBL] [Abstract][Full Text] [Related]
18. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
[TBL] [Abstract][Full Text] [Related]
19. Association of chromosome 10 losses and negative prognosis in oligoastrocytomas.
Bissola L; Eoli M; Pollo B; Merciai BM; Silvani A; Salsano E; Maccagnano C; Bruzzone MG; Fuhrman Conti AM; Solero CL; Giombini S; Broggi G; Boiardi A; Finocchiaro G
Ann Neurol; 2002 Dec; 52(6):842-5. PubMed ID: 12447941
[TBL] [Abstract][Full Text] [Related]
20. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
Xiong J; Liu Y; Li C; Zhu JJ; Ye ZR; Mao Y; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
